A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
Weijia Cai(Thomas Jefferson University), Andrew E. Aplin(Thomas Jefferson University)
Cited by 25
Related Papers
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
|Cancer Discovery|2019|482
Akt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma Cells
|Cancer Research|2010|194
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
|Nature Communications|2022|98
PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth
|Nature Communications|2019|79